Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebellar Neoplasms | 7 | 2022 | 434 | 1.490 |
Why?
|
| Medulloblastoma | 8 | 2021 | 540 | 1.450 |
Why?
|
| Brain Neoplasms | 14 | 2023 | 4849 | 1.440 |
Why?
|
| Glioma | 12 | 2023 | 1963 | 1.240 |
Why?
|
| Choroid Plexus Neoplasms | 2 | 2018 | 26 | 1.150 |
Why?
|
| Brain Stem Neoplasms | 4 | 2020 | 108 | 1.150 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2022 | 502 | 0.980 |
Why?
|
| Astrocytoma | 2 | 2021 | 321 | 0.750 |
Why?
|
| Neuroectodermal Tumors | 2 | 2020 | 35 | 0.740 |
Why?
|
| Anaphylaxis | 1 | 2020 | 119 | 0.690 |
Why?
|
| Fat Necrosis | 1 | 2019 | 63 | 0.690 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2019 | 160 | 0.660 |
Why?
|
| Ganglioglioma | 1 | 2018 | 41 | 0.640 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 1382 | 0.620 |
Why?
|
| Needs Assessment | 1 | 2018 | 233 | 0.570 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 231 | 0.560 |
Why?
|
| Rhabdoid Tumor | 2 | 2015 | 110 | 0.560 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 1283 | 0.540 |
Why?
|
| Ubiquitin | 1 | 2017 | 344 | 0.540 |
Why?
|
| Carcinoma | 2 | 2018 | 2578 | 0.510 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2017 | 589 | 0.500 |
Why?
|
| Chemoradiotherapy | 4 | 2018 | 1946 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 1350 | 0.460 |
Why?
|
| Consolidation Chemotherapy | 1 | 2013 | 155 | 0.440 |
Why?
|
| Neuroblastoma | 1 | 2018 | 686 | 0.430 |
Why?
|
| Child, Preschool | 15 | 2022 | 16273 | 0.410 |
Why?
|
| Ependymoma | 3 | 2020 | 242 | 0.410 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 10035 | 0.370 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 669 | 0.360 |
Why?
|
| Child | 22 | 2023 | 29154 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2018 | 15862 | 0.350 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 882 | 0.330 |
Why?
|
| Prognosis | 9 | 2023 | 21713 | 0.290 |
Why?
|
| Infant | 8 | 2021 | 13310 | 0.280 |
Why?
|
| Vincristine | 3 | 2020 | 1511 | 0.270 |
Why?
|
| DNA Methylation | 1 | 2016 | 2669 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 4757 | 0.250 |
Why?
|
| Histones | 3 | 2021 | 1466 | 0.250 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 904 | 0.240 |
Why?
|
| Survival Rate | 6 | 2019 | 12221 | 0.240 |
Why?
|
| Humans | 34 | 2023 | 261506 | 0.220 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 8865 | 0.220 |
Why?
|
| Infusions, Intraventricular | 2 | 2020 | 29 | 0.210 |
Why?
|
| Adolescent | 11 | 2023 | 31252 | 0.200 |
Why?
|
| Ganglioneuroma | 1 | 2020 | 41 | 0.190 |
Why?
|
| Fourth Ventricle | 2 | 2017 | 51 | 0.190 |
Why?
|
| Oligodendroglioma | 1 | 2021 | 106 | 0.190 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 328 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 183 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7702 | 0.170 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2019 | 63 | 0.170 |
Why?
|
| Female | 19 | 2023 | 141928 | 0.170 |
Why?
|
| Infant, Newborn | 4 | 2021 | 8223 | 0.170 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 119 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.160 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 133 | 0.160 |
Why?
|
| Mutation | 6 | 2021 | 15179 | 0.160 |
Why?
|
| Young Adult | 9 | 2023 | 21445 | 0.160 |
Why?
|
| Review Literature as Topic | 1 | 2018 | 71 | 0.160 |
Why?
|
| Infratentorial Neoplasms | 1 | 2017 | 45 | 0.150 |
Why?
|
| Pineal Gland | 1 | 2017 | 50 | 0.150 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 120 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 333 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10331 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 852 | 0.140 |
Why?
|
| Male | 13 | 2020 | 123000 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 336 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 6550 | 0.130 |
Why?
|
| International Agencies | 1 | 2015 | 107 | 0.130 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2015 | 81 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1411 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2014 | 54 | 0.120 |
Why?
|
| Middle Cerebellar Peduncle | 1 | 2014 | 5 | 0.120 |
Why?
|
| Pons | 1 | 2014 | 51 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 1546 | 0.120 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1165 | 0.120 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 10001 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 315 | 0.110 |
Why?
|
| Etoposide | 1 | 2015 | 870 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2023 | 1797 | 0.110 |
Why?
|
| Methotrexate | 1 | 2015 | 999 | 0.100 |
Why?
|
| Proton Therapy | 1 | 2022 | 1577 | 0.100 |
Why?
|
| Adult | 7 | 2023 | 77950 | 0.100 |
Why?
|
| Carboplatin | 1 | 2015 | 823 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 303 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2013 | 485 | 0.100 |
Why?
|
| Camptothecin | 1 | 2013 | 517 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 1242 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 13658 | 0.090 |
Why?
|
| Bevacizumab | 1 | 2013 | 938 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 669 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 1904 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 1914 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 6207 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 609 | 0.080 |
Why?
|
| Animals | 6 | 2020 | 59536 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 3001 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 37905 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2013 | 1824 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 5178 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2359 | 0.060 |
Why?
|
| Genomics | 1 | 2014 | 2738 | 0.060 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2104 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 3251 | 0.050 |
Why?
|
| Biomarkers | 1 | 2014 | 5047 | 0.050 |
Why?
|
| Brain Stem | 1 | 2022 | 175 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2012 | 2527 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 2796 | 0.050 |
Why?
|
| Thalamus | 1 | 2021 | 132 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2014 | 3341 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 473 | 0.040 |
Why?
|
| Lysine | 1 | 2020 | 422 | 0.040 |
Why?
|
| Everolimus | 1 | 2020 | 415 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 365 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2017 | 418 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 32848 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 905 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.030 |
Why?
|
| Chromatin | 1 | 2020 | 942 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 3842 | 0.030 |
Why?
|
| Anisotropy | 1 | 2014 | 181 | 0.030 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 1399 | 0.030 |
Why?
|
| Pyridines | 1 | 2019 | 1244 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2295 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 690 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 5395 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 1472 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 5112 | 0.020 |
Why?
|
| Incidence | 1 | 2021 | 5673 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 829 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3821 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6295 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 4113 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 1442 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 1094 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Mice | 2 | 2020 | 34495 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3719 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3536 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3639 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2019 | 3518 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 7226 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1859 | 0.020 |
Why?
|
| Apoptosis | 1 | 2019 | 7591 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 17523 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 6682 | 0.010 |
Why?
|